EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

Abstract Background In various cancers, overexpression of cyclooxygenase (COX)-2 and elevated prostaglandin (PG) E2 synthesis have been associated with tumor development and progression. The potential of COX-2 inhibitors in cancer prevention and treatment has been shown repeatedly; however, their cl...

Full description

Bibliographic Details
Main Authors: Anna Semmlinger, Viktoria von Schoenfeldt, Verena Wolf, Alexandra Meuter, Theresa Maria Kolben, Thomas Kolben, Christine Zeder-Goess, Florian Weis, Julia Gallwas, Rachel Wuerstlein, Kerstin Hermelink, Elisa Schmoeckel, Nadia Harbeck, Doris Mayr, Sven Mahner, Udo Jeschke, Nina Ditsch
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
Breast cancer
EP3
Prostaglandin E2
EP-receptor
COX-2
PGE2
Online Access:http://link.springer.com/article/10.1186/s12885-018-4286-9

Internet

http://link.springer.com/article/10.1186/s12885-018-4286-9

Similar Items